FDA to Review Satralizumab for Neuromyelitis Optica Spectrum Disorder
The FDA has accepted the Biologics License Application (BLA) for satralizumab (Genentech) for the treatment of neuromyelitis optica spectrum disorder.
Optic Neuritis
Thresholds Found for Unilateral Optic Nerve Lesions in Multiple Sclerosis
A new anatomic threshold may be useful for identifying unilateral optic nerve lesions in patients with multiple sclerosis.
Improvement in Acute Optic Neuritis Similar With IV, Oral Corticosteroids
The advantages of oral prednisone include “being less expensive and more convenient to access and administer and [being] preferred by patients to [intravenous] methylprednisolone.”
Inter-Eye Percentage Difference May Help Diagnose MS-Associated Optic Neuritis
Using the inter-eye percentage difference may help surpass limitations associated with device and proprietary segmentation algorithms.
RENEW Trial: Promising Results for Optic Neuritis Treatment
Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
Radiation Dose Influences Optic Neuropathy Risk
There were no significant associations for alternative risk factors after controlling for radiation dosage.
Anterior Visual Pathway Measures and Cognition in MS
There was a significant association between the average GCIP thickness and MSFC scores.
Antihistamine May Benefit Optic Neuropathy in Multiple Sclerosis
While the effect is modest, researchers believe the findings will influence future repair studies.
Epilepsy Drug May Be Neuroprotective in Optic Neuritis
Those treated with phenytoin saw a 30% reduction in retinal nerve fiber loss.
Anti-LINGO-1 May Repair Myelin Damage in Multiple Sclerosis
The drug was tested in patients with optic neuritis, but is now being evaluated in patients with multiple sclerosis.
-
Loading...
-
Loading...
Next post in AAN 2015 Coverage
